Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications

L. Sigalotti; S. Coral; M. Altomonte; L. Natali; G. Gaudino; P. Cacciotti; R. Libener; F. Colizzi; G. Vianale; F. Martini; M. Tognon; A. Jungbluth; J. Cebon; E. Maraskovsky; L. Mutti; M. Maio

doi:10.1038/sj.bjc.6600174

Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications

L. Sigalotti
, S. Coral
, M. Altomonte
, L. Natali
, G. Gaudino
, P. Cacciotti
, R. Libener
, F. Colizzi
, G. Vianale
, F. Martini
, M. Tognon
, A. Jungbluth
, J. Cebon
, E. Maraskovsky
, L. Mutti
, M. Maio

Research output: Contribution to journal › Article › peer-review

Abstract

Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.

Original language	English
Pages (from-to)	979-982
Number of pages	4
Journal	British Journal of Cancer
Volume	86
Issue number	6
DOIs	https://doi.org/10.1038/sj.bjc.6600174
Publication status	Published - 2002
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

5-aza-2′-deoxycytidine
Cancer testis antigens
Immunotherapy
Mesothelioma
Methylation

Access to Document

10.1038/sj.bjc.6600174

Cite this

Sigalotti, L., Coral, S., Altomonte, M., Natali, L., Gaudino, G., Cacciotti, P., Libener, R., Colizzi, F., Vianale, G., Martini, F., Tognon, M., Jungbluth, A., Cebon, J., Maraskovsky, E., Mutti, L., & Maio, M. (2002). Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications. British Journal of Cancer, 86(6), 979-982. https://doi.org/10.1038/sj.bjc.6600174

@article{6ba36ce2a31940118840a5ef45b4bebd,

title = "Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications",

abstract = "Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.",

keywords = "5-aza-2′-deoxycytidine, Cancer testis antigens, Immunotherapy, Mesothelioma, Methylation",

author = "L. Sigalotti and S. Coral and M. Altomonte and L. Natali and G. Gaudino and P. Cacciotti and R. Libener and F. Colizzi and G. Vianale and F. Martini and M. Tognon and A. Jungbluth and J. Cebon and E. Maraskovsky and L. Mutti and M. Maio",

note = "Funding Information: Supported in part by the Associazione Italiana per la Ricerca sul Cancro (M Maio and M Tognon), the CNR Target Project Biotechnology (M Tognon) and by the Progetto Ricerca Finalizzata awarded by the Italian Ministry of Public Health (M Maio).",

year = "2002",

doi = "10.1038/sj.bjc.6600174",

language = "English",

volume = "86",

pages = "979--982",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "6",

}

Sigalotti, L, Coral, S, Altomonte, M, Natali, L, Gaudino, G, Cacciotti, P, Libener, R, Colizzi, F, Vianale, G, Martini, F, Tognon, M, Jungbluth, A, Cebon, J, Maraskovsky, E, Mutti, L & Maio, M 2002, 'Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications', British Journal of Cancer, vol. 86, no. 6, pp. 979-982. https://doi.org/10.1038/sj.bjc.6600174

TY - JOUR

T1 - Cancer testis antigens expression in mesothelioma

T2 - Role of DNA methylation and bioimmunotherapeutic implications

AU - Sigalotti, L.

AU - Coral, S.

AU - Altomonte, M.

AU - Natali, L.

AU - Gaudino, G.

AU - Cacciotti, P.

AU - Libener, R.

AU - Colizzi, F.

AU - Vianale, G.

AU - Martini, F.

AU - Tognon, M.

AU - Jungbluth, A.

AU - Cebon, J.

AU - Maraskovsky, E.

AU - Mutti, L.

AU - Maio, M.

N1 - Funding Information: Supported in part by the Associazione Italiana per la Ricerca sul Cancro (M Maio and M Tognon), the CNR Target Project Biotechnology (M Tognon) and by the Progetto Ricerca Finalizzata awarded by the Italian Ministry of Public Health (M Maio).

PY - 2002

Y1 - 2002

N2 - Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.

AB - Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.

KW - 5-aza-2′-deoxycytidine

KW - Cancer testis antigens

KW - Immunotherapy

KW - Mesothelioma

KW - Methylation

UR - https://www.scopus.com/pages/publications/18344396043

U2 - 10.1038/sj.bjc.6600174

DO - 10.1038/sj.bjc.6600174

M3 - Article

SN - 0007-0920

VL - 86

SP - 979

EP - 982

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -

Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this